Comment on “Impact of TNF-Α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the catholic axial spondyloarthritis cohort (CASCO)”

  • Erkan CureEmail author
  • Medine Cumhur Cure
Letter to the Editor

Dear Sir,

We read with great pleasure the very important study evaluating the impact of tumor necrosis factor-alpha inhibitor (TI) on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis by Min HK et al. [1]. We would like to draw attention to some important points in this valuable study. In their study [1], the standard deviations of the AIP and cholesterol change difference values are too large. Both groups do not show the homogeneous distribution, for these values ​​must be given as median (range). The authors should use the Mann-Whitney U test instead of the t-test to compare nonhomogeneous data. P values may change with the proper statistical evaluation.

Ankylosing spondylitis (AS) is a rheumatologic disease with frequent cardiac involvement [2]. When the two groups’ baseline values were examined, the disease duration was significantly higher in the TI group than without the TI (TW) group [1]. The longer the disease duration will increase cardiovascular...


Compliance with ethical standards

Conflict of interest



  1. 1.
    Min HK, Lee J, Ju JH, Park SH, Kwok SK (2019) Impact of TNF-α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the Catholic axial Spondyloarthritis COhort (CASCO). Clin Rheumatol 1–7.
  2. 2.
    Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA (2018) Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clin Rheumatol 37:1273–1280CrossRefGoogle Scholar
  3. 3.
    Bergström U, Jovinge S, Persson J, Jacobsson LTH, Turesson C (2018) Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr Ther Res Clin Exp 89:1–6CrossRefGoogle Scholar
  4. 4.
    Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME (2010) A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 29:947–955CrossRefGoogle Scholar
  5. 5.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:921–923PubMedGoogle Scholar
  6. 6.
    Maneiro JR, Souto A, Gomez-Reino JJ (2017) Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. Clin Rheumatol 36:1167–1172CrossRefGoogle Scholar
  7. 7.
    Maia DG, Augusto KL, Bezerra MC, Rodrigues CEM (2017) Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol 36:2371–2376CrossRefGoogle Scholar
  8. 8.
    Kucuk A, Uğur Uslu A, Icli A, Cure E, Arslan S, Turkmen K, Toker A, Kayrak M (2017) The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis. Z Rheumatol 76:58–63CrossRefGoogle Scholar
  9. 9.
    Karimifar M, Sepehrifar MS, Moussavi H, Sepehrifar MB, Mottaghi P, Siavash M et al (2018) The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. J Res Med Sci 23:105PubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2020

Authors and Affiliations

  1. 1.Department of Internal MedicineOta & Jinemed HospitalIstanbulTurkey
  2. 2.Department of BiochemistryPrivate PracticeIstanbulTurkey

Personalised recommendations